MedTrace Logo

A Study of GPC3-targeted T Cells by Intratumor Injection for Advanced HCC (GPC3-CART)

NCT03130712 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2017-04-26

No results posted yet for this study

Summary

In this study, CART cells are targeted to GPC3 by intratumor injected that we hope by this means could improve the local CAR-T cell numbers, meanwhile reduce the potential side effects.

Conditions

  • Carcinoma, Hepatocellular

Interventions

DRUG

GPC3-CART cells

Intratumol injection as a local drug delivery pathway, so that more T cells gathered at the tumor site, less T cells to migrated to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects. And GPC3-CART is a 2nd CAR, with GPC3 as the target protein, 4-1BB as a co- stimulator

Sponsors & Collaborators

  • Beijing 302 Hospital

    collaborator OTHER

  • Shanghai GeneChem Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Lu Yinying, Doctor · Beijing 302 Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
69 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-01
Primary Completion
2018-03-31
Completion
2018-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03130712 on ClinicalTrials.gov